Barchart on MSN2h
What to Expect From Pfizer's Next Quarterly Earnings Report
Valued at a market cap of $152.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company dedicated to advancing ...
American Airlines' focus on ESG in 401(k) plan is illegal, US judge rules
A federal judge in Texas on Friday said American Airlines violated federal law by basing investment decisions for its ...
Pfizer must face lawsuit over diversity fellowship program, US court rules
(Reuters) - A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in ...
Hosted on MSN6h
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
Investing7h
Delta Air Lines, Walgreens and TSMC rise premarket; Nvidia, AMD fall
Taiwan Semiconductor Manufacturing (NYSE: TSM) stock rose 1.2% after the world’s biggest contract chipmaker reported ...
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...
Pfizer (NYSE:PFE) Price Target Lowered to $29.00 at UBS Group
Pfizer (NYSE:PFE – Get Free Report) had its price objective lowered by analysts at UBS Group from $31.00 to $29.00 in a ...
Pfizer (NYSE:PFE) Stock Price Down 0.8% on Analyst Downgrade
Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price fell 0.8% during trading on Thursday after UBS Group lowered their price target on the stock from $31.00 to $29.00. UBS Group currently has a ...
Royalty Pharma Announces Dividend Increase
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ...